Börse:

Biocartis Group NV

[WKN: A14R82 | ISIN: BE0974281132]

0,260€

Echtzeit-Aktienkurs Biocartis Group NV

Bid: Ask:

Nachrichten zur Biocartis Group NV Aktie

» Nachrichtenticker öffnen

Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting

BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 09 May 2024, 07:00 CEST…

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)

BIOCARTIS GROUP NV (Euronext Brussels: BCART)…

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)

BIOCARTIS GROUP NV (Euronext Brussels: BCART)…

Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors

PRESS RELEASE REGULATED INFORMATION 31 October 2023, 15:30 CET…

Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)

PRESS RELEASE 20 October 2023, 07:00 CEST…

Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio

PRESS RELEASE 16 October 2023, 7:00 CEST…

Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit

PRESS RELEASE 12 October 2023, 7:00 CEST…

Press release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023

PRESS RELEASE REGULATED INFORMATION …

Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders

PRESS RELEASE: 28 August 2023, 7:00 AM CEST...…

Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023

PRESS RELEASE: 24 August 2023, 07:00 CEST...…

Press Release Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ Platform

PRESS RELEASE: 10 August 2023, 07:00 CEST...…

Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery

PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION18 July 2023, 7:00 AM CEST...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: Disclosure of transparency notification

PRESS RELEASE - REGULATED INFORMATION 20 June 2023, 17:40 CEST...…

XFRA : 8XB: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

XFRA : 8XB: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : INSTRUMENT_SUSPENSION - BE0974281132

Instrument ID [1389] (8XB - BE0974281132) suspended...…

Press release Biocartis Group NV: Biocartis announces planned operational reorganization and cost reduction program

PRESS RELEASE ...…

Press release Biocartis Group NV: Disclosure of transparency notification

PRESS RELEASE...…

Press release Biocartis Group NV: Biocartis announces resignation CFO

PRESS RELEASE...…

Press release Biocartis Group NV: Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test

PRESS RELEASE: 9 May 2023, 07:00 CEST...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE: REGULATED INFORMATION28 April 2023, 17:40 CEST...…

Press release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2023

PRESS RELEASE: REGULATED INFORMATION20 April 2023, 07:00 CEST...…

Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO

PRESS RELEASE: INSIDE INFORMATION/ REGULATED INFORMATION11 April 2023, 22:00 CEST...…

Press release Biocartis Group NV: Biocartis Announces Publication of 2022 Annual Report

PRESS RELEASE: REGULATED INFORMATION...…

Press release Biocartis Group NV: Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™ platform

PRESS RELEASE: 4 April 2023, 07:00 CEST...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION ...…

Press release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: Disclosure of transparency notification

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test

PRESS RELEASE...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: Biocartis announces 2022 results and 2023 outlook

PRESS RELEASE - REGULATED INFORMATION23 February 2023, 07:00 CET...…

Press release Biocartis Group NV: Biocartis announces change in Board composition

PRESS RELEASE...…

Press release Biocartis Group NV: Biocartis Announces 2022 Full Year Results on 23 February 2023

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: Biocartis Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

PRESS RELEASE...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION...…

Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES

PRESS RELEASE: REGULATED INFORMATION17 January 2023, 17:40 CET...…

Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions

PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET...…

Press release Biocartis Group NV: Disclosure of transparency notifications

PRESS RELEASE: REGULATED INFORMATION 4 January 2023, 17:40 CET...…

Press release Biocartis Group NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION 22 December 2022, 17:45 CET...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE: REGULATED INFORMATION22 December 2022, 17:40 CET...…

Press release Biocartis Group NV: Completion of Mandatory Conversion

PRESS RELEASE: REGULATED INFORMATION16 December 2022, 17:40 CET...…

Press release Biocartis Group NV: Disclosure of transparency notifications

PRESS RELEASE: REGULATED INFORMATION 9 December 2022, 17:40 CET...…

Press release Biocartis Group NV: Mandatory Conversion Bondholder Notification

PRESS RELEASE: REGULATED INFORMATION5 December 2022, 17:40 CET...…

Press release Biocartis Group NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION 2 December 2022, 17:45 CET...…

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE: REGULATED INFORMATION...…

China Biopsy Market Report to 2027 - Featuring Thermo Fisher Scientific, Bio-Rad Laboratories, Exact Sciences, Biocept, Biocartis and Roche Diagnostics Among Others

DUBLIN, Dec. 2, 2022 /PRNewswire/ -- The "China Biopsy Market, Volume, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation,…

Press release Biocartis Group NV: Biocartis Announces Successful Rights Offering

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION29 November 2022, 15:15 CET...…

Press release Biocartis Group NV: Biocartis Announces 55.91% of Offered Shares Subscribed at Closing of Rights Subscription Period for Holders of Preferential Rights, and Start of Sale of Scrips through Private Placement to Inst. Investors

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION...…